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Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved
by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study
ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related
macular degeneration are underway. The results are promising and may impact patient care.
1. Introduction
The vitreous occupies approximately 80% of the eye and is
composed of water, collagen fibers, and hyaluronic acid [1].
In children, the vitreous is normally attached to the retinal
surface and relatively innocuous. With aging, the vitreous
physiologically liquefies and separates from the retina in a
process called posterior vitreous detachment (PVD). The
strongest points of vitreoretinal attachment are at the optic
nerve, central retina (macula), blood vessels, and ora serrata.
At any age, the vitreous can be abnormally adherent
to the macula, leading to sight-threatening diseases such as
vitreomacular traction and macular hole [2, 3]. Vitreomac-
ular traction is also implicated in the worsening of diabetic
retinopathy and exudative age-related macular degeneration
(AMD). Traditionally, diseases of the vitreoretinal interface
have been treated with surgery to mechanically detach the
vitreous from the retina and improve vision.
Vitreous surgery carries inherent risks such as bleeding,
infection, retinal detachment, and accelerated cataract for-
mation. Furthermore, inducing vitreous separation from the
retina, particularly in the setting of an abnormal vitreoretinal
interface, is among the most technically challenging and
dangerous steps of vitreous surgery. Therefore, pharmaco-
logical vitreolysis has been an important research goal in
ophthalmology [4].
Ocriplasmin (Microplasmin, ThromboGenics, Iselin,
NJ) is a medicine that may be injected into the vitreous and
administered in an office setting. It is a new technique to
pharmacologically induce a posterior vitreous detachment
by cleaving the extracellular matrix that adheres the vitreous
to the internal limiting membrane of the retina [5–7]. The
biomedical rationale and status of ocriplasmin for vitreoreti-
nal diseases are discussed herein.
2. Plasmin Receptors in the Eye
Plasmin, the key enzyme of the fibrinolytic cascade, is also
known to cleave other extracellular matrix components,
specifically laminin and fibronectin [8–10]. In the eye, both
molecules localize to the vitreoretinal interface, where they
are postulated to play a central role in the adherence of
collagen fibers between the vitreous and the internal limiting
membrane (ILM) [11–17].
Early work showing the efficacy of plasmin in inducing a
posterior vitreous detachment (PVD) was largely performed
in rabbit eyes. Verstraeten et al. [18] initially demonstrated
that intravitreal injection of plasmin followed by mechanical
core vitrectomy successfully induced a PVD, as was later
confirmed by histologic analysis. Hikichi et al. [19] aiming
to avert the need for vitrectomy, subsequently combined
intravitreal injection of plasmin with SF6 gas into rabbit
eyes to successfully create a PVD without any signs of retinal
toxicity. Interestingly, plasmin given alone was not sufficient
to induce PVD in either study [18, 19]. In contrast to the
previous reports, which investigated the intraocular effects of
plasmin after only 1 week, Kim et al. [20] followed plasmin-
injected rabbit eyes for 4 months, with no significant toxicity
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observed. Additionally, they showed that plasmin alone was
sufficient to produce a clean separation between the vitreous
cortex and retina [20].
Gandorfer et al. [21] demonstrated that the degree of
vitreoretinal separation induced by plasmin directly corre-
lates with the concentration as well as length of exposure
to the enzyme. Porcine eyes exposed to 1 unit of plasmin
for 30 minutes had a dense network of residual collagen
fibrils covering the ILM, while those exposed to 1 unit
of plasmin for 60 minutes had only sparse collagen fibrils
remaining. Furthermore, eyes treated with 2 units of plasmin
for 60 minutes had a smooth retinal surface on postmortem
examinations, consistent with a bare ILM. A later study by
the same group was the first to duplicate these results in
human cadaver eyes, and without any evidence of induced
retinal damage [22].
Li et al. [23] separately investigated administration of
intravitreal plasmin injections in human cadaver eyes. Us-
ing electron microscopy, they observed progressively less
evidence of vitreous collagen fibers on the retinal surface
with increasing doses of plasmin administered (1, 2, and 3
units) without producing morphological changes or acute
toxicity to the inner retina. Through immunocytochemical
labeling techniques, they were also able to demonstrate that
treatment with plasmin dramatically decreased the density
of fibronectin and laminin at the ILM. Uemura et al. [24]
additionally confirmed through Western blot analyses that
fibronectin and laminin were degraded by plasmin to several
fragments of lower molecular weight in the ILMs collected
from patients with macular holes or cystoid macular edema
who underwent vitrectomy.
Cleavage of fibronectin and laminin may actually offer
only a partial explanation to the molecular basis of phar-
macologic vitreous detachment. Given that laminin and
fibronectin are present at other ocular tissues beyond the
vitreoretinal interface, such as the lens, ciliary body, retinal
vessels, and lamina cribrosa [14], how is it that intravitreal
plasmin injection can induce a PVD without adversely
affecting these other structures? The answer may lie in
plasmin’s additional ability to activate endogenous matrix
metalloproteinases (MMP), namely MMP-2 (gelatinase A),
which normally reside within the vitreous in their proen-
zyme state [25–30]. Due to its affinity for various collagens,
notably basement membrane type IV, activation of MMP-2
by exogenous plasmin likely contributes to the formation of
PVD [26].
Beyond creating a PVD, Brown et al. [27] showed that
experimentally injected active MMP-2-cleaved bovine vitre-
ous collagen and concluded that MMP-2 activity could be
considered a potential mechanism for the vitreous liquefac-
tion seen in aging as well as various pathologic states. Animal
studies suggest that plasmin, likely through activation of
MMP-2, may also liquefy the vitreous and be of particular
benefit as an adjunct to small-gauge vitrectomy systems.
This, in turn, may facilitate both easier and increased vit-
reous removal during vitrectomy, while shortening duration
of surgery. Staubach et al. [31] measured a greater reduction
in the wet weight of enucleated porcine eyes injected with
plasmin compared with controls once the vitreous was
removed by core vitrectomy. Corroborating these findings,
Hermel et al. [32] observed a 27% increase in rate of vitreous
removal through a 25-gauge cutting system in rabbit eyes
injected with plasmin as compared with no injection.
Clinically, autologous plasmin has been utilized as an
adjunct to vitrectomy in numerous patient cohorts. Given
the robust vitreoretinal adhesion in pediatric patients, Trese
and colleagues investigated the utility of plasmin-assisted
vitrectomy in the repair of traumatic macular holes [33, 34],
stage 5 retinopathy of prematurity [35], and complicated X-
linked retinoschisis [36], reporting successful anatomic out-
comes in all groups. The use of plasmin-assisted vitrectomy
to treat stage 3 full-thickness macular holes has revealed
higher rates of spontaneous PVD noted intraoperatively in
conjunction with reduction in overall surgery time [24, 37–
39]. Other investigators employing preoperative plasmin in
cases of tractional diabetic macular edema found higher
incidences of spontaneous PVD at the time of surgery [40,
41], less suction required to create a PVD when needed [42],
and improved postoperative visual outcomes compared with
controls [41]. Hirata et al. [43] observed that plasmin pre-
treatment in patients with proliferative diabetic retinopathy
resulted in significantly less surgical time and a decreased risk
for iatrogenic retinal breaks.
Unfortunately, autologous plasmin has several shortcom-
ings which limit its feasibility for routine clinical practice.
First, it is not readily available, and the process to obtain it
is time-consuming and expensive. Autologous plasminogen
must be harvested from the patient’s own blood, then
converted by streptokinase to plasmin in vitro prior to use.
Second, this procedure must be done immediately before
surgery as plasmin is exceedingly unstable and rapidly
inactivates itself via autolysis and binding to α2-antiplasmin.
Recent advances in pharmaceutical drug development
led to the discovery of ocriplasmin (Microplasmin), a recom-
binant product of only the catalytic domain of human plas-
min [44]. Distinct advantages of ocriplasmin over plasmin
include. (1) it is approximately one-fourth the size of plasmin
(22-kDa versus 88-kDa) which is thought to facilitate greater
penetration of vitreous and epiretinal tissues; (2) generation
by recombinant techniques ensures product sterility and
eliminates the risk of microbial contamination associated
with blood derivatives; (3) when commercially available, it
will allow investigators to avoid the rigorous preparation of
autologous plasmin; (4) it is more stable than plasmin which
simplifies storage and timing of administration [45].
Intravitreal ocriplasmin has been evaluated in several
preclinical studies utilizing porcine, rat, rabbit, feline, and
human cadaver eyes as the experimental model [46–48].
Gandorfer et al. initially reported a dose- and time-depend-
ent cleavage between the posterior hyaloid and the ILM
created by ocriplasmin without any adverse effects on retinal
structure, in both human cadaver and feline eyes. Doses
greater than or equal to 125.0 μg (equivalent to 2 units of
plasmin (Sigma-Aldrich, Poole, United Kingdom)) produced
a complete PVD with bare ILM in the human eyes, as
demonstrated by electron microscopy.
De Smet et al. [49] confirmed these findings in a porcine
eye model, observing that microplasmin caused vitreolysis
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and PVD in a dose- and time-dependent fashion. The
minimal effective dose also appeared to be 125 μg [49].
Sakuma et al. [50] corroborated these findings as well in
rabbit eyes using doses of microplasmin ranging from 12.5
to 250 μg. They, too, found that 125 μg of microplasmin or
greater successfully induced a complete PVD, while lower
doses only induced a partial PVD. In all treated eyes, there
was a temporary reduction in the a- and b-wave amplitudes
on electroretinography, which recovered by 14 days after
injection all groups except the 250 μg treatment group. In this
higher dose faction, while the b-wave eventually recovered,
a-wave alterations persisted at 90 days. A mild, transient
vitreous haze was also noted within the first day after
injection in this and other studies [12, 50, 51].
Most recently, Chen et al. [12] were able to show
through immunofluorescence histochemistry that intravit-
real microplasmin degraded fibronectin and laminin not
only at the vitreoretinal interface, but also at the level of the
photoreceptor layer in the outer retina of rats. Theoretically,
the smaller molecular weight of ocriplasmin facilitates deep-
er penetration of retinal tissue but it is uncertain if this holds
true in humans.
3. Clinical Trials with Ocriplasmin
In 2004, a series of clinical trials sponsored by ThromboGen-
ics were initiated and collectively called Microplasmin for
IntraVitreous Injection- Tractional Release without Surgical
Treatment (MIVI-TRUST). To date, there are 14 studies
involving intravitreal administration of ocriplasmin (Clini-
calTrials.gov). Of these, 9 are included in the MIVI series.
Results of the first three clinical trials (MIVI-I, MIVI-IIT, and
MIVI-III) are published [7, 18, 19].
In each of these clinical trials, all patients with prior vit-
reous surgery and/or history of retinal detachments were
excluded. Adverse events were also recorded and none of
these studies have thus far shown an increased rate of retinal
detachment, a known complication of posterior vitreous
detachment, after ocriplasmin therapy.
3.1. MIVI-I: A Dose-Escalation Clinical Trial of Intravitreal
Microplasmin in Patients Undergoing Surgical Vitrectomy for
Vitreomacular Traction Maculopathy. MIVI-I was a Phase
I/II safety study with dose escalation (25–125 micrograms)
and increasing exposure time (1 hour–1 week) [7]. Sixty
patients were enrolled in 6 successive cohorts. All patients
had vitreomacular traction (VMT) maculopathy for which
vitrectomy was indicated, including macular edema asso-
ciated with VMT, stage II-III macular hole of <6 months
duration since symptom onset, demonstration of vitreomac-
ular adhesion (VMA) based on preoperative optic coherence
tomography (OCT), or an OCT finding of posterior hyaloid
membrane inserting onto the macula but with some area of
clear separation visible between the retina and the posterior
hyaloid. Results demonstrated that intravitreal ocriplasmin
was well tolerated and capable of inducing a pharmacologic
PVD in some patients.
3.2. MIVI-II: A Randomized, Sham-Injection-Controlled,
Double-Masked, Ascending-Dose, Dose-Range-Finding Trial
of Microplasmin Intravitreal Injection for Nonsurgical PVD
Induction for Treatment of Diabetic Macular Edema. MIVI-
II was a Phase II trial evaluating PVD induction in patients
with diabetic macular edema (DME) 14 days after injection
of intravitreal ocriplasmin versus sham. Disease status and
safety at 6 months were also evaluated. The study was com-
pleted in 2010; however, results have not yet been published
at the time of this paper.
3.3. MIVI-IIT: A Randomized, Sham-Injection-Controlled,
Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of
Microplasmin Intravitreal Injection for Nonsurgical PVD
Induction for Treatment of Vitreomacular Traction. MIVI-
IIT was a randomized, double-masked Phase II trial with a
control sham injection [18]. Sixty patients were enrolled in
4 cohorts. Patients in each of the cohorts were randomized
to active treatment or sham injection. In the first 3 cohorts,
increasing doses of ocriplasmin (75, 125, and 175 micro-
grams) were administered. In the fourth cohort, patients
received 125micrograms of intravitreal ocriplasminmonthly
until the VMA was released, up to a total of 3 doses.
The first 3 cohorts had a nonsurgical resolution of VMA
in 8, 25, 44, and 27% of the patients who received sham, 75,
125, and 175 micrograms of ocriplasmin, respectively. In the
fourth cohort, ocriplasmin caused a PVD in 58% of patients
at one month after the last treatment.
The MIVI-IIT trial provides support for the potential use
of ocriplasmin in the nonsurgical treatment of VMA.
3.4. MIVI-III: A Multicenter, Randomized, Placebo-Con-
trolled, Double-Masked, Parallel-Group, Dose-Ranging Clini-
cal Trial of Intravitreal Microplasmin in Patients Undergoing
Surgical Vitrectomy The MIVI III (Microplasmin for Vitreous
Injection III) Trial. MIVI–III evaluated the safety and effi-
cacy of a preoperative intravitreal injection of ocriplasmin
in patients already scheduled for vitreous surgery [19]. One
hundred twenty-five patients scheduled for pars plana vitrec-
tomy (PPV) for the treatment of either VMT or macular hole
were enrolled in this Phase II placebo-controlled double-
masked dose-ranging clinical trial. A single intravitreal
injection of ocriplasmin (25, 75, or 125 micrograms) or
placebo was administered 7 days prior to PPV. The presence
or absence of PVD at baseline, injection day, operative day,
and postinjection day 90 and 180 were evaluated.
Rates of PVD observed at the time of surgery were 10,
14, 18, and 31% in the placebo, 25-, 75-, and 125-microgram
ocriplasmin groups, respectively. The rates of resolution of
VMT precluding the need for PPV at day 35 were 3, 10,
15, and 31% for the placebo, 25-, 75-, and 125-microgram
ocriplasmin groups, respectively. At day 180, these rates were
3%, 7%, 15%, and 28%. At both day 35 and day 180, the rates
of canceled vitrectomy in the 125-microgram ocriplasmin
group were statistically significant when compared to the
placebo group (P < 0.01 and P = 0.01, resp.).
MIVI-III concluded that ocriplasmin injection at a dose
of 125 micrograms led to a greater likelihood of induction
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and progression of PVD than placebo injection. This study
also suggested that patients receiving ocriplasmin were more
likely to not require vitrectomy surgery and that further trials
were warranted.
3.5. MIVI-5: A Randomized, Sham-Injection-Controlled, Dou-
ble-Masked, Multicenter Trial of Ocriplasmin Intravitreal
Injection for Treatment of Focal Vitreomacular Adhesion in
Subjects with Exudative Age-Related Macular Degeneration
(AMD). Exudative AMD is a serious cause of blindness
in elderly patients, and current standard of care includes
monthly intravitreal antivascular endothelial growth factor
(VEGF) injections [52]. Vitreomacular traction is thought
to exacerbate AMD by exerting tractional forces on the
macula, hypothetically stimulating abnormal blood vessel
growth.
MIVI-5 is an ongoing clinical trial evaluating the safety
and efficacy of intravitreal ocriplasmin in patients diagnosed
with exudative AMD with focal VMA. Patients enrolled in
this study have active subfoveal choroidal neovascular mem-
brane and have received at least 3 antiangiogenic intravitreal
injections, with evidence of focal VMA on OCT. Patients
who have previously received more than 9 antiangiogenic
intravitreal injections are excluded.
The primary outcome measure is the proportion of
patients with release of focal VMA by day 28 as determined
by a masked central reading center. MIVI-5 started in early
2010 and completion is anticipated in late 2012.
3.6. MIVI-TRUST (TG-MV-006): A Randomized, Placebo-
Controlled, Double-Masked, Multicenter Trial of Microplasmin
Intravitreal Injection for Nonsurgical Treatment of Focal
Vitreomacular Adhesion and MIVI-TRUST (TG-MV-007): A
Randomized, Placebo-Controlled, Double-Masked, Multicen-
ter Trial of Microplasmin Intravitreal Injection for Nonsurgical
Treatment of Focal Vitreomacular Adhesion. MIVI-TRUST
TG-MV-006 and TG-MV-007 are both Phase III clinical trials
evaluating the safety and efficacy of a 125-microgram dose
of intravitreal ocriplasmin in patients with focal VMA. The
primary outcome measure was the nonsurgical resolution of
focal VMA at postinjection day 28. Both studies began late
2008 and were completed in 2010. Final published results
from these 2 studies are not yet available.
3.7. MIVI-8: An Open-Label, Single-Centre Trial of Microplas-
min Intravitreal Injection for Nonsurgical Treatment of Focal
Vitreomacular Adhesion. MIVI-8 is a Phase II clinical trial
assessing the safety and efficacy of 125-microgram ocriplas-
min administered as an intravitreal injection in patients
with focal VMA. Primary outcome measures include full
ophthalmologic examination at baseline, postinjection days
7, 14, 28, and months 3 and 6. A secondary outcome is the
proportion of patients with nonsurgical resolution of focal
VMA at study visits other than the 28-day postinjection visit.
MIVI-8 completed in April 2011 and published results are
currently pending.
3.8. MIVI-10: An Open-Label, Ascending-Exposure-Time,
Single-Center Trial to Evaluate the Pharmacokinetic Properties
of Ocriplasmin (Generic Name of the Molecule Microplasmin)
Intravitreal Injection in Subjects Scheduled for Primary Pars
Plana Vitrectomy. The purpose of MIVI-10 is to evaluate
the pharmacokinetic properties of intravitreal ocriplasmin
when administered at different time points prior to planned
PPV. In this Phase II clinical trial, 38 patients undergoing
primary PPV received an intravitreal injection of 125-
microgram ocriplasmin 5 minutes to 7 days prior to surgery.
Ocriplasmin activity levels in the vitreous samples were
evaluated. The study completed in early 2011 and final results
have not yet been published.
3.9. Non-MIVI Trials. In addition to theMIVI-TRUST trials,
there are 4 other trials that are currently evaluating the
use of intravitreal ocriplasmin(ClinicalTrials.gov). A single-
center, placebo-controlled Phase II clinical trial is actively
enrolling patients to assess the efficacy of a high-dose
(1.875 milligram) intravitreal injection of ocriplasmin in
the treatment of focal VMA in patients with exudative
AMD. Besides improving AMDby eliminating vitreomacular
traction, ocriplasmin may also affect the pharmacokinetics
and efficacy of anti-VEGF agents. A study in rabbits showed
that bevacizumab (an anti-VEGF agent) in combination with
ocriplasmin facilitated the penetration of bevacizumab into
the retina [53]. The secondary endpoint of this clinical trial
involving AMD and ocriplasmin is a decrease in subsequently
required anti-VEGF injections.
Another study recruiting patients is Ocriplasmin for
Treatment of Symptomatic Vitreomacular Adhesion Includ-
ing Macular Hole (OASIS), a Phase II clinical trial evaluat-
ing the treatment of symptomatic vitreomacular adhesion
including macular hole with a single 125-microgram intrav-
itreal injection of ocriplasmin.
Additionally, the Microplasmin Intravitreal Administra-
tion in Participants with Uveitic Macular Edema is an
ongoing Phase I/II trial investigating the safety and potential
efficacy of intravitreal ocriplasmin as a possible treatment for
macular edema secondary to uveitis. This study was initiated
in 2010 and is anticipated to conclude in early 2012.
Finally, the Microplasmin in Children (MIC) Trial is
also recruiting patients to assess the safety and efficacy
of intravitreal ocriplasmin as an adjunct to conventional
vitrectomy for the treatment of pediatric patients under 16
years of age. The vitreous in children is denser and more
adherent to the retina as compared with that in adults,
and the safety and efficacy profile of ocriplasmin may differ
in children and adults. This Phase II, placebo-controlled,
double-masked trial will evaluate a 175-microgram dose of
ocriplasmin in pediatric patients undergoing a standard 2-
port or 3-port PPV. Any child diagnosed with Stage 1, 2, 3, or
5 retinopathy of prematurity (ROP) at the time of the surgery
is excluded.
In summary, the safety and efficacy of ocriplasmin for
vitreoretinal diseases are being systematically evaluated in
over a dozen clinical trials. The medicine is meant to help
some patients avoid surgery or at least make vitreous surgery
safer in others.
Journal of Biomedicine and Biotechnology 5
4. Federal Drug Administration Approval
In December 2011, a Federal Drug Administration (FDA)
application was submitted for the use of ocriplasmin
2.5mg/mL in adults. It was withdrawn and resubmitted
for Priority Review in April 2012. If FDA approved, future
applications for ocriplasmin would include its use in more
common vitreomacular diseases such as diabetic retinopathy
and vein occlusions.
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